Facilitation of morphine withdrawal symptoms and morphine-induced conditioned place preference by a glutamate transporter inhibitor DL-threo-β-benzyloxyaspartate in rats

European Journal of Pharmacology

Volumn 485, Issue 1-3, 2004, Pages 201-210

  Sekiya, Yumiko ^a   Nakagawa, Takayuki ^a   Ozawa, Tohru ^a   Minami, Masabumi ^a   Satoh, Masamichi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Conditioned place aversion; Conditioned place preference; DL threo benzyloxyaspartate; Glutamate transporter; Morphine dependence; Morphine withdrawal

Indexed keywords

ASPARTIC ACID DERIVATIVE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMATE TRANSPORTER; MORPHINE; NALOXONE; THREO BETA BENZYLOXYASPARTATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; AVERSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

EID: 1642456595     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.11.062     Document Type: Article

References (62)

1. Aghajanian G.K., Kogan J.H., Moghaddam B. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study. Brain Res. 636:1994;126-130.
2. Akaoka H., Aston-Jones G. Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J. Neurosci. 11:1991;3830-3839.
3. Bespalov A., Dumpis M., Piotrovsky L., Zvartau E. Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. Eur. J. Pharmacol. 264:1994;233-239.
4. Bisaga A., Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend. 59:2000;1-15.
5. Blokhina E.A., Sukhotina I.A., Bespalov A.Y. Pretreatement with morphine potentiates naloxone-conditioned place aversion in mice: effects of NMDA receptor antagonists. Eur. J. Pharmacol. 406:2000;227-232.
6. Bristow L.J., Hogg J.E., Hutson P.H. Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats. Neuropharmacology. 36:1997;241-250.
7. Carlezon W.A. Jr., Boundy V.A., Haile C.N., Lane S.B., Kalb R.G., Neve R.L., Nestler E.J. Sensitization to morphine induced by viral-mediated gene transfer. Science. 277:1997;812-814.
8. Christie M.J., Williams J.T., Osborne P.B., Bellchambers C.E. Where is the locus in opioid withdrawal? Trends Pharmacol. Sci. 18:1997;134-140.
9. Del Arco A., Gonzalez-Mora J.L., Armas V.R., Mora F. Amphetamine increases the extracellular concentration of glutamate in striatum of the awake rat: involvement of high affinity transporter mechanisms. Neuropharmacology. 38:1999;943-954.
10. Del Pozo E., Barrios M., Baeyens J.M. The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice. Psychopharmacology. 125:1996;209-213.
11. Donzanti B.A., Uretsky N.J. Effects of excitatory amino acids on locomotor activity after bilateral microinjection into the rat nucleus accumbens: possible dependence on dopaminergic mechanisms. Neuropharmacology. 22:1983;971-981.
12. Fitzgerald L.W., Ortiz J., Hamedani A.G., Nestler E.J. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J. Neurosci. 16:1996;274-282.
13. Frenois F., Cador M., Caillé S., Stinus L., Moine C.L. Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur. J. Neurosci. 16:2002;1377-1389.
14. Fundytus M.E., Coderre T.J. Morphine dependence is affected by activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors. Br. J. Pharmacol. 113:1994;1215-1220.
15. Fundytus M.E., Ritchie J., Coderre T.J. Attenuation of morphine withdrawal symptoms by subtype-selective metabotropic glutamate receptor antagonists. Br. J. Pharmacol. 120:1997;1015-1020.
16. Gibson R.D., Tingstad J.E. Formulation of a morphine implantation pellet suitable for tolerance-physical dependence studies in mice. J. Pharm. Sci. 59:1970;426-427.
17. González P., Cabello P., Germany A., Norris B., Contreras E. Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur. J. Pharmacol. 332:1997;257-262.
18. Gracy K.N., Dankiewicz L.A., Koob G.F. Opiate withdrawal-induced Fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology. 24:2001;152-160.
19. Higgins G.A., Sellers E.M. Antagonist-precipitated opioid withdrawal in rats: evidence for dissociations between physical and motivational signs. Pharmacol. Biochem. Behav. 48:1994;1-8.
20. Higgins G.A., Nguyen P., Sellers E.M. The NMDA antagonist dizocilpine (MK-801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. Life Sci. 50:1992;PL167-PL172.
21. Johnson S.W., Seutin V., North R.A. Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science. 258:1992;665-667.
22. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18:1993;75-113.
23. Kalivas P.W., Duffy P., Barrow J. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J. Pharmacol. Exp. Ther. 251:1989;378-387.
24. Kanai Y., Smith C.P., Hediger M.A. The elusive transporters with a high affinity for glutamate. Trends Neurosci. 16:1993;365-370.
25. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
26. Krebs M.O., Desce J.M., Kemel M.L., Gauchy C., Godeheu G., Cheramy A., Glowinski J. Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J. Neurochem. 56:1991;81-85.
27. Lebrun B., Sakaitani M., Shimamoto K., Yasuda-Kamatani Y., Nakajima T. New β-hydroxyaspartate derivatives are competitive blockers for the bovine glutamate/aspartate transporter. J. Biol. Chem. 272:1997;20336-20339.
28. Le Guen S., Gestreau C., Besson J.M. Sensitivity to naloxone of the behavioral signs of morphine withdrawal and c-Fos expression in the rat CNS: a quantitative dose-response analysis. J. Comp. Neurol. 433:2001;272-297.
29. Maldonado R., Stinus L., Gold L.H., Koob G.F. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261:1992;669-677.
30. Manning B.H., Mao J.R., Frenk H., Price D.D., Mayer D.J. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 67:1996;79-88.
31. Mao J., Sung B., Ji R.-R., Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J. Neurosci. 22:2002;8312-8323.
32. McLemore G.L., Kest B., Inturrisi C.E. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. Brain Res. 778:1997;120-126.
33. Mennerick S., Zorumski C.F. Glial contributions to excitatory neurotransmission in cultured hippocampal cells. Nature. 368:1994;59-62.
34. Moghaddam B., Bolinao M.L. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse. 18:1994;337-342.
35. 3 receptor-selective agonists of morphine withdrawal syndrome in rats. Eur. J. Pharmacol. 390:2000;257-266.
36. Nakagawa T., Ozawa T., Shige K., Yamamoto R., Minami M., Satoh M. Inhibition of morphine tolerance and dependence by MS-153, a glutamate transporter activator. Eur. J. Pharmacol. 419:2001;39-45.
37. Narita M., Aoki T., Suzuki T. Molecular evidence for the involvement of NR2B subunit containing N-methyl-D-aspartate receptors in the development of morphine-induced place preference. Neuroscience. 101:2000;601-606.
38. Ozawa T., Nakagawa T., Shige K., Minami M., Satoh M. Changes in the expression of glial glutamate transporters in the rat brain accompanied with morphine dependence and naloxone-precipitated withdrawal. Brain Res. 905:2001;254-258.
39. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. 1998;Academic Press, San Diego.
40. Popik P., Danysz W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate antagonist, memantine. J. Pharmacol. Exp. Ther. 280:1997;854-865.
41. Popik P., Kolasiewicz W. Mesolimbic NMDA receptors are implicated in the expression of conditioned morphine reward. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;288-294.
42. Popik P., Wróbel M. Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist. Neuropharmacology. 43:2002;1210-1217.
43. Rasmussen K., Vandergriff J. The selective iGluRl-4 (AMPA) antagonist LY300168 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioural signs of morphine withdrawal. Neuropharmacology. 44:2003;88-92.
44. Rasmussen K., Fuller R.W., Stockton M.E., Perry K.W., Swinford R.M., Ornstein P.L. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur. J. Pharmacol. 117:1991;9-16.
45. Rasmussen K., Kendrick W.T., Kogan J.H. A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology. 15:1996;497-505.
46. Rezayof A., Zarrindast M.-R., Sahraei H., Haeri-Rohani A. Involvement of dopamine D2 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat. Pharmacol. Biochem. Behav. 74:2002;187-197.
47. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., Kanai Y., Hediger M.A., Wang Y., Schielke J.P., Welty D.F. Knockout of glutamate transporters reveals a major role for astroglial transport in excitatory and clearance of glutamate. Neuron. 16:1996;675-686.
48. Seal R.P., Amara S.G. Excitatory amino acid transporters: a family in flux. Annu. Rev. Pharmacol. Toxicol. 39:1999;431-456.
49. Seutin V., Johnson S.W., North R.A. Effect of dopamine and baclofen on N-methyl-D-aspartate-induced burst firing in rat ventral tegmental neurons. Neuroscience. 58:1994;201-206.
50. Shigeri Y., Shimamoto K., Yasuda-Kamatani Y., Seal R.P., Yumoto N., Nakajima T., Amara S.G. Effects of threo-β-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J. Neurochem. 79:2001;297-302.
51. Shimamoto K., LeBrun B., Yasuda-Kamatani Y., Sakaitani M., Shigeri Y., Yumoto N., Nakajima T. DL-threo-β-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol. Pharmacol. 53:1998;195-201.
52. Stinus L., LeMoal M., Koob G.F. Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience. 37:1990;767-773.
53. Suzuki T., Kato H., Tsuda M., Suzuki H., Misawa M. Effects of the non-competitive NMDA receptor antagonist ifenprodil on the morphine-induced place preference in mice. Life Sci. 64:1999;PL151-PL156.
54. Tanaka K., Watase K., Manabe T., Yamada K., Watanabe M., Takahashi K., Iwama H., Nishikawa T., Ichihara N., Kikuchi T., Okuyama S., Kawashima N., Hori S., Takimoto M., Wada K. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 276:1997;1699-1702.
55. Tokuyama S., Zhu H., Oh S., Ho I.K., Yamamoto T. Further evidence for a role of NMDA receptors in the locus coeruleus in the expression of withdrawal syndrome from opioids. Neurochem. Int. 39:2001;103-109.
56. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
57. Tzschentke T.M., Schmidt W.J. N-methyl-D-aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats. Neurosci. Lett. 193:1995;37-40.
58. Watanabe T., Nakagawa T., Yamamoto R., Maeda A., Minami M., Satoh M. Involvement of glutamate receptors within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Jpn. J. Pharmacol. 88:2002;399-406.
59. Watanabe T., Yamamoto R., Maeda A., Nakagawa T., Minami M., Satoh M. Effects of excitotoxic lesions of the central or basolateral nucleus of the amygdala on naloxone-precipitated withdrawal-induced conditioned place aversion in morphine-dependent rats. Brain Res. 958:2002;423-428.
60. Yoburn B.C., Chen J., Huang T., Inturrisi C.E. Pharmacokinetics and pharmacodynamics of subcutaneous morphine pellets in the rat. J. Pharmacol. Exp. Ther. 235:1985;282-285.
61. Zhang J., Chiodo L.A., Freeman A.S. Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res. 590:1992;153-163.
62. Zhu H., Rockhold R.W., Ho I.K. The role of glutamate in physical dependence on opioids. Jpn. J. Pharmacol. 76:1998;1-14.